Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 17/20 | 0.88 |
| ▸ | NOS3 | P29474 | 14/20 | 0.88 |
| ▸ | NOS2 | P35228 | 12/20 | 0.88 |
| ▸ | HTR1B | P28222 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833992 | 0.96 | NOS1 (0.86) | NOS1NOS3NOS2HTR1B | |
| SCHEMBL5833967 | 0.94 | NOS1 (1.00) | NOS1NOS3NOS2HTR1B | |
| SCHEMBL7082993 | 0.89 | NOS1 (0.86) | NOS1NOS3NOS2HTR1B | |
| SCHEMBL5833522 | 0.84 | NOS1 (0.78) | NOS1NOS3NOS2HTR1B | |
| SCHEMBL5833697 | 0.83 | NOS3 (0.76) | NOS1NOS3NOS2 | |
| SCHEMBL7078132 | 0.80 | NOS3 (0.68) | NOS1NOS3NOS2HTR1B | |
| SCHEMBL8399599 | 0.80 | NOS1 (0.67) | NOS1NOS3NOS2HTR1B | |
| SCHEMBL7085842 | 0.79 | NOS3 (0.67) | NOS1NOS3NOS2HTR1B | |
| SCHEMBL7078114 | 0.79 | NOS3 (0.66) | NOS1NOS3NOS2HTR1B | |
| SCHEMBL252053 | 0.79 | NOS1 (0.73) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012078-B2 | 2-aminopyridines containing fused ring substituents | PFIZER INC. (US) | 2006-03-14 | — | — | US | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-7012078-B2 | 2-aminopyridines containing fused ring substituents | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1007520-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PROD INC (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | LOWE JOHN A (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN ADAMS (US) | 2001-12-06 | — | — | US | disclosed |
| EP-1109556-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-1007520-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-2000009130-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999010339-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | NOS1 2/4885NOS3 3/4885NOS2 1/4885 |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | NOS1, NOS3, NOS2 | NOS1 1/4885NOS3 2/4885NOS2 3/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | NOS1 1/4885NOS3 2/4885NOS2 6/4885 |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | NOS1 2/4885NOS3 3/4885NOS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.